Key result
PCSK9 inhibitors reduce plasma homocysteine ~29% at 12 weeks in familial hypercholesterolemia.
Why the study?
PCSK9 inhibitors reduce LDL-C and cardiovascular risk, but their effects on plasma homocysteine and broader vascular-metabolic pathways in familial hypercholesterolemia remain poorly characterized.
Does PCSK9 inhibitor therapy reduce plasma homocysteine and modify related vascular–metabolic biomarkers over 12 weeks in adults with familial hypercholesterolemia?
Cohort (n=50)
No
Does PCSK9 inhibitor therapy reduce plasma homocysteine and modify related vascular–metabolic biomarkers over 12 weeks in adults with familial hypercholesterolemia?
Twelve weeks of PCSK9 inhibitor therapy in patients with familial hypercholesterolemia was associated with significant reductions in plasma homocysteine and urinary isoprostane oxidative stress markers alongside expected LDL-C and Lp(a) lowering.
Answers are grounded in this paper and cite their sources.
PCSK9 inhibitor effects on homocysteine in FH remain unclear from this cohort; leaves open any impact on vascular-metabolic risk.
Background Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors reduce low-density lipoprotein cholesterol (LDL-C) and cardiovascular risk, but their effects on homocysteine (Hcy) and broader vascular–metabolic pathways remain poorly characterized. Objective To evaluate changes in plasma Hcy and related vascular–metabolic biomarkers during PCSK9 inhibitor treatment in patients with familial hypercholesterolemia (FH). Methods In this prospective, single-center observational cohort study, 50 patients with FH initiating a PCSK9 inhibitor were evaluated at baseline and after 12 weeks. The primary endpoint was the within-subject change in plasma Hcy. Paired assessments included lipid parameters, urinary oxidative stress markers, biomarkers of the arginine–nitric oxide pathway, and ancillary untargeted metabolomic profiling. Results Mean Hcy decreased from 12.6 ± 6.7 to 8.9 ± 2.4 µmol/L, a 29% reduction, while median Hcy decreased from 10.7 µmol/L (IQR, 9.0–13.4) to 9.1 µmol/L (IQR, 7.0–10.5), a 15% reduction (P < 0.001). Hyperhomocysteinemia (> 15 µmol/L) resolved in all 10 affected patients (P = 0.002). Total cholesterol, corrected LDL-C, and lipoprotein(a) decreased by 37.9%, 34.1%, and 35.2%, respectively. Urinary F₂-isoprostanes, DH-isoprostanes, and dinor-isoprostane metabolites also decreased significantly, whereas arginine–nitric oxide pathway biomarkers did not. Multivariable analysis identified coordinated associations between ΔHcy and methylmalonic acid, arginine–nitric oxide metabolites, LDL-C reduction, and lipoprotein(a). Metabolomics showed sterol and phospholipid remodeling, lower choline abundance, and a higher putative betaine-related signal. Conclusion PCSK9 inhibition was associated with reduced Hcy, marked lipid remodeling, and lower oxidative stress in FH, supporting further investigation of Hcy as a treatment-responsive biomarker of broader vascular–metabolic remodeling. This response may help characterize vascular biology during intensive lipid-lowering therapy in high-risk FH.
No takes yet. Share an insight, caveat, or question.
Calcaterra et al. (2026) conducted a cohort in Familial hypercholesterolemia (n=50). PCSK9 inhibitor therapy (evolocumab or alirocumab) vs. Baseline (within-subject paired comparison before initiation) was evaluated on Within-subject change in plasma homocysteine from baseline (T0) to 12 weeks (T12) (MD -3.7 µmol/L, p=<0.001). PCSK9 inhibitor treatment reduced mean plasma homocysteine by 29% over 12 weeks in patients with familial hypercholesterolemia.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: